F. Rocha
Bial
25 Papers
53 Citations
F. Rocha is an academic researcher from Bial. The author has contributed to research in topics: Eslicarbazepine acetate & Post-hoc analysis. The author has an hindex of 5, co-authored 23 publications.
Chat about Author
Papers
Psychiatric and cognitive adverse events: A pooled analysis of three phase III trials of adjunctive eslicarbazepine acetate for partial-onset seizures.
Eva Andermann,Victor Biton,Selim R. Benbadis,Bassel F. Shneker,Aashit Shah,Mar Carreño,Eugen Trinka,Elinor Ben-Menachem,Arnaud Biraben,F. Rocha,Helena Gama,Hailong Cheng,David Blum,Study,Investigators (Appendix ) +14 more
TL;DR: In phase III clinical trials of adjunctive ESL for treatment-refractory POS, psychiatric and cognitive TEAEs were reported infrequently with ESL and placebo, but there was no notable trend between increasing ESL dose and increasing incidence of depression and suicidality-relatedTEAEs.
14
Severity and burden of partial-onset seizures in a phase III trial of eslicarbazepine acetate.
Joyce A. Cramer,Fulton Velez,Kathryn Anastassopoulos,T. Christopher Bond,Frank Gilliam,Philippe Ryvlin,Luigi Maria Specchio,Xuezhe Wang,David Blum,Joana Moreira,F. Rocha +10 more
TL;DR: This study presents Class I evidence that adjunctive ESL doses led to clinically meaningful, dose-dependent seizure severity reductions, measured by the SSQ, as measured by SSQ scores.
11
Serum sodium levels and related treatment-emergent adverse events during eslicarbazepine acetate use in adults with epilepsy.
Robert T. Wechsler,Rodney A. Radtke,Michael C. Smith,David G. Vossler,Laura Strom,Eugen Trinka,Hailong Cheng,Todd Grinnell,David Blum,Mariana Vieira,Joana Moreira,F. Rocha +11 more
TL;DR: The frequency of hyponatremia and potentially related symptoms in clinical trials of eslicarbazepine acetate (ESL) in adults with focal‐ (partial‐) onset seizures is examined.
8
Exposure-safety and efficacy response relationships and population pharmacokinetics of eslicarbazepine acetate.
Barry E. Gidal,Mercedes P. Jacobson,Elinor Ben-Menachem,Mar Carreño,David Blum,Patrício Soares-da-Silva,Amílcar Falcão,F. Rocha,Joana Moreira,Todd Grinnell,Elizabeth Ludwig,Jill Fiedler-Kelly,Julie A. Passarell,Soujanya Sunkaraneni +13 more
TL;DR: In this article, the authors developed a pharmacokinetic and pharmacodynamic (PD) model to assess dose selection, identify significant AED drug interactions, and quantitate relationships between exposure and safety and efficacy outcomes from Phase 3 trials of adjunctive ESL.
8
Absorption, metabolism and excretion of opicapone in human healthy volunteers
Ana I. Loureiro,F. Rocha,Ana-Teresa Santos,Nand Singh,Maria João Bonifácio,Rui Pinto,László L. Kiss,Patrício Soares-da-Silva +7 more
TL;DR: The absorption, metabolism and excretion of opicapone (2,5‐dichloro‐3‐(5‐[3, 4‐dihydroxy‐5‐nitrophenyl]‐1,2,4‐oxadiazol‐3-yl)‐4,6‐dimethylpyridine 1‐oxide), a selective catechol‐O‐methyltransferase inhibitor, were investigated.
4